Medical device maker Emulate Therapeutics (EMTX) has set terms for a proposed IPO that would raise around $13M. Emulate said in a filing that it is looking to offer 2.5M shares priced between $4 and ...

Issuance of U.S. Design Patent No. D944,999 S advances EMulate Therapeutics' Intellectual Portfolio to 41 issued US and foreign patents. BELLEVUE, WA / ACCESSWIRE / March 7, 2022 / EMulate ...

EMulate Therapeutics, Inc. (EMTX) has filed proposed terms for a $12.5 million IPO of its common stock, according to an amended S-1/A registration statement. The company is developing medical device ...

BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma ...

EMulate Therapeutics, Inc. (EMTx) announces the acceptance of a publication of its pre-clinical animal model, testing the effect of its ulRFE® paclitaxel (A1A) signal against a DIPG tumor cell line.

Feb. 9 (UPI) --A team from Binghamton University has created a reusable, multilayered and microfluidic device that emulates human kidney function. The device incorporates a porous growth substrate, ...

As hardware can be costly and difficult to obtain, it is paramount that researchers have methods to emulate device firmware in order to study how devices work and look into their vulnerabilities. For ...

Issuance of U.S. Patent No. 11,103,721 B2 advances EMulate Therapeutics' Intellectual Portfolio to 38 issued US and foreign patents SEATTLE, WA / ACCESSWIRE / September 28, 2021 / EMulate Therapeutics ...